 |
SV Life Sciences Fund IVSVLSF IV closed in February 2007 with total commitments of $550 million (plus $22 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010 the Fund had invested $316 million in 37 portfolio companies. To go to individual portfolio companies websites please click on company logo. Biotechnology / Biopharmaceuticals
Adimab: US
First investment: 2007 - Start Up Adimab, Inc. is developing a fully integrated platform for antibody discovery and manufacturing which will offer customers/ acquirers a 3rd party royalty free and very rapid, 2-3 month path from target to optimized antibody. 
Affinium Pharmaceuticals : US
First investment: 2007 - Early Stage Affinium Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of novel anti-infective medicines stemming from the bacterial fatty acid synthesis pathway. 
Allocure: US
First investment: 2008 - Early Stage Allocure is a biotechnology company at the forefront of innovative cell therapies for the treatment of acute kidney injury. Antiva: UK First investment: 2008 - Start Up Antiva, is a spin out business from Vantia www.vantiatherapeutics.com and alongside that business focuses on leading research based healthcare into improving clinical treatments through development & commercialisation of innovative medicines. 
Delenex Therapeutics: Switzerland
First investment SVLSF IV: 2009 - Early Stage Delenex is a spin out from ESBATech, an investment that was divested in 2009. The business focuses on research and development in to its antibody fragments for delivering next generation Therapeutics application. 
EUSA Pharma : UK
First investment: 2007 - Expansion EUSA Pharma (EUSA) is a fast growing, transatlantic specialty pharma company developing and commercialising for healthcare professionals and patients a range of prescription products in pain, oncology and critical care. 
Itero Biopharmaceuticals: US
First investment: 2007 - Early Stage Itero is an early stage biosimilars company focused on the large number of product opportunities with product patents. 
Juvaris BioTherapeutics: US
First Investment: 2009 - Early Stage Developing novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. 
Link Medicine: US
First Investment: 2008 - Early Stage Link Medicine is a clinical stage company spun out of Harvard University working on disease-modifying therapies for neurodegenerative diseases. 
Logical Therapeutics: US
First investment: 2007 - Start Up Logical Therapeutics is a clinical stage drug development company with a focus on inflammation. The lead product, LT-NS001, is a prodrug of naproxen designed to minimize GI toxicity. The company is also working on a prodrug of aspirin, also designed to minimize GI toxicity. 
Mpex Pharmaceuticals: US
First SVLSF IV Investment: 2009 - Early Stage Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex’s first product will be an inhaled antibiotic for serious lung infections. 
NeurogesX (NGSX): US
First Investment: 2007 - PIPE NeurogesX is developing novel topical products to relieve chronic pain and improve quality of life. 
NKT Therapeutics, Inc: US
First Investment: 2007 - Early Stage NKT Therapeutics is a biotechnology company focused on developing therapeutics based on a unique subset of immune cells called natural killer T (”NKT”) cells. 
Ophthotech: US
First investment: 2007 - Seed Ophthotech is dedicated to developing drugs for ophthalmic diseases with high unmet medical needs. PanOptica First investment: 2009 - Seed PanOptica is a start-up company dedicated to developing drugs for ophthalmic diseases with high unmet medical needs. 
RespiVert: UK - Exited
First Investment: 2007 - Start Up RespiVert is a discovery company focused on Chronic obstructive pulmonary disease ('COPD') and severe asthma. The company’s goal is to develop novel inhaled and intranasal drugs for respiratory disorders with high unmet medical need and high commercial potential based on novel insights on biology and chemistry. 
Vantia Pharmaceuticals: UK
First investment: 2008 - Start Up Vantia Therapeutics is a leading research based healthcare company dedicated to improving clinical treatments through development & commercialisation of innovative medicines. 
X2-Pharma: Germany - Exited
First investment: 2008 - Seed X2-Pharma is a biopharmaceutical company dedicated to the discovery and development of small molecule pharmaceuticals for the treatment of inflammatory diseases. 
| |
